An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
FSD Pharma Announces Filing of Year-End 2021 Results
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ: HUGE) has filed its Annual Report on Form 20-F for the year ended December 31, 2021, which includes audited financial results and management discussion. The filings are accessible via SEDAR and EDGAR profiles. The company is focused on developing biotech solutions, with three drug candidates in various stages. FSD BioSciences, a subsidiary, is advancing its lead compound, ultra-micronized palmitoyl ethylamine (FSD-PEA). Lucid Psycheceuticals, another subsidiary, is working on compounds targeting mental health and neurodegenerative disorders.
Positive
Completion of Annual Report filing indicating regulatory compliance.
Three drug candidates in development, showcasing a diverse pipeline.
FSD BioSciences and Lucid Psycheceuticals focused on significant medical needs.
Negative
None.
TORONTO--(BUSINESS WIRE)--
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis.
These filings are available for review under the Company's SEDAR profile at www.sedar.com and the Company’s EDGAR profile at www.sec.gov.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”), a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
